Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era
Journal
The oncologist
Journal Volume
25
Journal Issue
9
Pages
793
Date Issued
2020-09
Author(s)
Huang, Sheng-Chuan
Chen, Jia-Hong
Wei, Chao-Hung
Fang, Wei-Quan
Abstract
Patients with diffuse large B-cell lymphoma (DLBCL) with concurrent hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection have distinct clinical features. Nevertheless, the prognostic value of HBsAg in DLBCL in the rituximab era remains unclear.
Subjects
Diffuse large B-cell lymphoma; Hepatitis B surface antigen; Hepatitis B virus infection; Prognosis; Risk stratification
Other Subjects
albumin; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; hepatitis B core antibody; hepatitis B surface antigen; hepatitis B(e) antigen; hepatitis C virus antibody; lactate dehydrogenase; rituximab; unclassified drug; antineoplastic agent; cyclophosphamide; doxorubicin; hepatitis B surface antigen; prednisone; rituximab; vincristine; adult; aged; antigen detection; Article; autologous stem cell transplantation; cancer prognosis; clinical feature; clinical outcome; cohort analysis; diffuse large B cell lymphoma; female; follow up; hepatitis B; human; liver failure; lymphocyte count; major clinical study; male; monocyte count; multiple cycle treatment; outcome assessment; overall survival; prevalence; priority journal; prognostic assessment; progression free survival; prophylaxis; retrospective study; treatment response; validation process; virus load; virus reactivation; prognosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hepatitis B Surface Antigens; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prognosis; Retrospective Studies; Rituximab; Vincristine
Publisher
WILEY